NCT00430898View on ClinicalTrials.gov

Basiliximab in Moderate to Severe Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Ulcerative Colitis
Interventions
DRUG

Basiliximab

3 doses of 40mg, IV at baseline, week 2, and week 4

Trial Locations (68)

3000

Leuven

15143

Sewickley

32789

Winter Park

40536

Lexington

44195

Cleveland

46202

Indianapolis

49074

Dnipro

58104

Fargo

60637

Chicago

61037

Kharkiv

61801

Urbana

66606

Topeka

76000

Ivano-Frankivsk

76104

Fort Worth

77090

Houston

95661

Roseville

110076

New Delhi

115446

Moscow

121309

Moscow

141001

Ludhiana

214001

Smolensk

226014

Lucknow

400016

Mumbai

443011

Samara

500012

Hyderabaad

682017

Kochi

700020

Kolkata

Unknown

Anaheim

Golden

Littleton

Hollywood

Jacksonville

Atlanta

Troy

Great Neck

New York

Germantown

Galveston

Prague

Gdansk

Krakow

02114

Boston

08234

Egg Harbor Twp

293 50

Mladá Boleslav

100 34

Prague

170 00

Prague

390 03

Tábor

562 18

Ústí nad Orlicí

560 054

Bangalore

530 002

Visakhapatnam

31-826

Krakow

60-353

Poznan

81-756

Sopot

81-820

Sopot

02-098

Warsaw

54-144

Wroclaw

811 07

Bratislava

851 01

Bratislava

949 01

Nitra

915 01

Nové Mesto nad Váhom

080 01

Prešov

01021

Kyiv

04210

Kyiv

BS2 8HW

Bristol

DE22 3NE

Derbyshire

WC1E 6DB

London

ST4 6QB

Stoke-on-Trent

WN1 2NN

Wigan

Sponsors
All Listed Sponsors
lead

Cerimon Pharmaceuticals

INDUSTRY